Preclinical studies have demonstrated that TNF blockade enhances the therapeutic effect of anti-PD-1 treatment, elevating tumor rejection rates from 20% with anti-PD-1 alone to 75% when combined with TNF inhibition.336,337. Here, TNF is linked to neoplasm.